secwatch.observer — SEC 8-K summary
======================================

Issuer:     RIGEL PHARMACEUTICALS INC (RIGL)
CIK:        0001034842
Form:       8-K
Filed at:   2022-08-02T23:59:59+00:00
Accession:  0001104659-22-085188
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.02, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rigel Q2 TAVALISSE net product sales $18.6M; licenses olutasidenib from Forma; draws $10M term loan
--------------------------------------------------------------------------------

- TAVALISSE net product sales of $18.6M, up 9% YoY; total revenues $29.8M; net loss $13.5M ($0.08/share).
- Exclusive license from Forma for olutasidenib (mIDH1 inhibitor) for R/R AML; $2M upfront, up to $233M milestones; PDUFA Feb 15, 2023.
- Amended MidCap credit agreement: extended maturity to Sept 2026, interest-only to Oct 2024; drew $10M fourth tranche term loan.
- Completed enrollment (280 patients) in Phase 3 COVID-19 trial of fostamatinib; top-line data expected Q4 2022.
- Knight license for TAVALISSE in Latin America: $2M upfront, up to $20M milestones; Kissei NDA submitted in Japan for ITP.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1034842/000110465922085188/0001104659-22-085188-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1034842/000110465922085188/tm2222339d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-085188

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer